Herrera, Alex F
City Of Hope National Medical Center · City of Hope
3 papers on CoChatORCID 0000-0002-9665-7415
Most cited papers
- Verified
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 2,286
- Verified
Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity
Jacobson, C. A., Hunter, B. D., Redd, R., Rodig, S. J., Chen, P.-H., Wright, K., Lipschitz, M., Ritz, J., Kamihara, Y., Armand, P., et al. (2020) · Journal of Clinical Oncology
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 352
- Verified
A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Siddiqi, T., Jacobson, C. A., Westin, J. R., Chavez, J. C., Ghobadi, A., Herrera, A. F., LaCasce, A. S., et al. (2016) · Blood
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 27
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free